EE200300575A - Asitromütsiini kristalsed vormid - Google Patents

Asitromütsiini kristalsed vormid

Info

Publication number
EE200300575A
EE200300575A EEP200300575A EEP200300575A EE200300575A EE 200300575 A EE200300575 A EE 200300575A EE P200300575 A EEP200300575 A EE P200300575A EE P200300575 A EEP200300575 A EE P200300575A EE 200300575 A EE200300575 A EE 200300575A
Authority
EE
Estonia
Prior art keywords
azithromycin
crystalline forms
crystalline
forms
Prior art date
Application number
EEP200300575A
Other languages
English (en)
Estonian (et)
Inventor
Jane Li Zheng
Vincent Trask Andrew
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300575A publication Critical patent/EE200300575A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200300575A 2001-05-22 2002-05-01 Asitromütsiini kristalsed vormid EE200300575A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US29774101P 2001-06-12 2001-06-12
US34304101P 2001-12-21 2001-12-21
PCT/IB2002/001570 WO2002094843A1 (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Publications (1)

Publication Number Publication Date
EE200300575A true EE200300575A (et) 2004-04-15

Family

ID=27404135

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300575A EE200300575A (et) 2001-05-22 2002-05-01 Asitromütsiini kristalsed vormid

Country Status (35)

Country Link
US (10) US6977243B2 (es)
EP (1) EP1390377B1 (es)
JP (3) JP2004530703A (es)
KR (1) KR100574153B1 (es)
AP (1) AP2003002906A0 (es)
AR (1) AR036022A1 (es)
AT (2) ATE319730T1 (es)
AU (1) AU2002256846B2 (es)
BG (1) BG108370A (es)
BR (1) BR0209918A (es)
CA (1) CA2391659C (es)
CR (1) CR7159A (es)
CZ (1) CZ20033154A3 (es)
DE (2) DE60228345D1 (es)
DK (1) DK1390377T3 (es)
EA (2) EA007618B1 (es)
EE (1) EE200300575A (es)
ES (2) ES2258142T3 (es)
GE (1) GEP20084399B (es)
HU (1) HUP0400446A2 (es)
IL (1) IL158591A0 (es)
IS (1) IS7007A (es)
MA (1) MA27023A1 (es)
MX (1) MXPA03010028A (es)
MY (1) MY129319A (es)
NO (2) NO321894B1 (es)
NZ (2) NZ529118A (es)
PA (1) PA8545701A1 (es)
PE (1) PE20021064A1 (es)
PL (1) PL367091A1 (es)
PT (1) PT1390377E (es)
SK (1) SK14402003A3 (es)
TN (1) TNSN03121A1 (es)
WO (1) WO2002094843A1 (es)
YU (1) YU91603A (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
CN100339384C (zh) * 1998-11-30 2007-09-26 特瓦制药工业有限公司 阿齐霉素的乙醇化物，制备方法以及医药组合物
DE60114028T2 (de) * 2000-08-23 2006-07-13 Wockhardt Ltd. Verfahren zur herstellung von wasserfreiem azithromycin
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
PT1390377E (pt) * 2001-05-22 2006-06-30 Pfizer Prod Inc Nova forma cristalina da azitromicina
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
PL371125A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Methods for wet granulating azithromycin
PL371259A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Directly compressible formulations of azithromycin
NZ534234A (en) 2002-02-01 2007-05-31 Pfizer Prod Inc Dry granulated formulations of non-dihydrate form of azithromycin
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1878432A1 (en) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Single dose fast dissolving azithromycin
US7572773B2 (en) 2003-07-24 2009-08-11 Pliva Hrvatska D.O.O. Single dose fast dissolving azithromycin
CA2678165C (en) * 2003-11-17 2013-11-05 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
JP2008501657A (ja) * 2004-06-02 2008-01-24 サンド・アクチエンゲゼルシヤフト 結晶形態のメロペネム中間体
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
WO2007004230A2 (en) * 2005-07-05 2007-01-11 Hetero Drugs Limited A novel process for the preparation of didanosine using novel intermediates
EP1904510A1 (en) * 2005-07-14 2008-04-02 Pfizer Products Incorporated Process for forming amorphous azithromycin particles
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
CN101389617A (zh) * 2005-10-31 2009-03-18 詹森药业有限公司 制备哌嗪基和二氮杂环庚烷基苯甲酰胺衍生物的新方法
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
NZ576347A (en) * 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
WO2010103119A1 (en) 2009-03-13 2010-09-16 Da Volterra Compositions and methods for elimination of gram-negative bacteria
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
US8343970B2 (en) 2010-03-12 2013-01-01 Omeros Corporation PDE10 inhibitors and related compositions and methods
SG10201506865WA (en) * 2010-09-01 2015-10-29 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
WO2013044816A1 (en) * 2011-09-30 2013-04-04 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan and preparation and uses thereof
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
RU2017134509A (ru) 2015-04-24 2019-04-04 Омерос Корпорейшн Ингибиторы pde10 и соответствующие композиции и способы
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43116B (en) * 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) * 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
KR100524214B1 (ko) * 1996-07-29 2005-11-01 아보트 러보러터리즈 클라리트로마이신의 제2 결정형의 제조 방법
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
CN100339384C (zh) * 1998-11-30 2007-09-26 特瓦制药工业有限公司 阿齐霉素的乙醇化物，制备方法以及医药组合物
US6703372B1 (en) * 1999-06-29 2004-03-09 Biochemie S.A. Macrolides
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
IL150564A0 (en) 2000-01-04 2003-02-12 Teva Pharma Preparation method of azithromycin dihydrate
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
WO2002010144A1 (es) * 2000-07-25 2002-02-07 Laboratorio Silanes, S.A. De C.V. PROCESO PARA LA PREPARACION EN UN SOLO PASO DE 7,16-DIOXA-2-AZA-10-O-CLADINOSIL-12-O-DESOSAMINIL-4,5-DIHIDROXI-6-ETIL-3,5,9,11,13,15-HEXAMETILBICICLO[11.2.1]HEXADECA-1(2)-EN-8-ONA Y OBTENCION DE UNA FORMA NUEVA DE 9-DESOXO-9a-AZA-9a-METIL-9a-HOMOERITROMICINA A
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
DE60114028T2 (de) 2000-08-23 2006-07-13 Wockhardt Ltd. Verfahren zur herstellung von wasserfreiem azithromycin
JP2004519430A (ja) 2000-11-27 2004-07-02 バイオケミ・エセ・ア マクロライドの溶媒和物
IN190080B (es) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
PT1390377E (pt) * 2001-05-22 2006-06-30 Pfizer Prod Inc Nova forma cristalina da azitromicina
AU2002335087A1 (en) 2001-10-18 2003-04-28 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions

Also Published As

Publication number Publication date
NO20061049L (no) 2003-05-12
CR7159A (es) 2004-02-23
EA200301115A1 (ru) 2004-04-29
DE60209704D1 (de) 2006-05-04
ES2258142T3 (es) 2006-08-16
MY129319A (en) 2007-03-30
ATE404575T1 (de) 2008-08-15
AR036022A1 (es) 2004-08-04
CA2391659A1 (en) 2002-11-22
SK14402003A3 (sk) 2004-06-08
HUP0400446A2 (hu) 2004-09-28
MA27023A1 (fr) 2004-12-20
AP2003002906A0 (en) 2003-12-31
ES2310886T3 (es) 2009-01-16
US6977243B2 (en) 2005-12-20
US20040043944A1 (en) 2004-03-04
DE60228345D1 (de) 2008-09-25
EP1390377B1 (en) 2006-03-08
BG108370A (bg) 2004-11-30
NO20035177D0 (no) 2003-11-21
US20050256063A1 (en) 2005-11-17
GEP20084399B (en) 2008-06-10
US7053192B2 (en) 2006-05-30
PL367091A1 (en) 2005-02-21
US20030162730A1 (en) 2003-08-28
EA007618B1 (ru) 2006-12-29
PE20021064A1 (es) 2002-11-21
US20050090459A1 (en) 2005-04-28
WO2002094843A1 (en) 2002-11-28
EP1390377A1 (en) 2004-02-25
US20050256062A1 (en) 2005-11-17
CA2391659C (en) 2006-05-30
CZ20033154A3 (en) 2004-04-14
BR0209918A (pt) 2004-03-30
JP2004530703A (ja) 2004-10-07
IL158591A0 (en) 2004-05-12
US7307156B2 (en) 2007-12-11
NO321894B1 (no) 2006-07-17
PT1390377E (pt) 2006-06-30
NZ529118A (en) 2005-10-28
US20050245469A1 (en) 2005-11-03
US7105179B2 (en) 2006-09-12
AU2002256846B2 (en) 2007-04-05
EA200500630A1 (ru) 2006-02-24
NZ539801A (en) 2006-10-27
KR100574153B1 (ko) 2006-04-25
ATE319730T1 (de) 2006-03-15
JP4584162B2 (ja) 2010-11-17
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
IS7007A (is) 2003-10-30
US20040138149A1 (en) 2004-07-15
MXPA03010028A (es) 2004-02-12
KR20040014525A (ko) 2004-02-14
TNSN03121A1 (en) 2005-12-23
JP2006152002A (ja) 2006-06-15
US7282486B2 (en) 2007-10-16
US20040082527A1 (en) 2004-04-29
DE60209704T2 (de) 2006-11-16
JP2007161726A (ja) 2007-06-28
YU91603A (sh) 2006-08-17
EA009611B1 (ru) 2008-02-28
US7081525B2 (en) 2006-07-25
DK1390377T3 (da) 2006-06-19
US7309782B2 (en) 2007-12-18
US20040043945A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
EE200300575A (et) Asitromütsiini kristalsed vormid
DK1451192T3 (da) Ny krystallinsk forbindelse
NO20043110L (no) Direkte komprimerbare formuleringer av azitromycin
ATE402148T1 (de) Substituierte pyridinylamine
PT1406628E (pt) Derivados de tera-hidroquinolina
DK3266791T3 (da) Mærkede nukleotider
DE60212857D1 (de) Thermischer schnappschalter
DK1522539T3 (da) Krystallinsk komposition indeholdende excitalopram
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
ATE430129T1 (de) Substituierte thioacetamide
FI20021262A (fi) Sokerien kiteytys
DE50206892D1 (de) Substituierte imidazotriazinone
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE02796975T1 (de) Hochtemperatur-gasreformier-zykloverbrennungsvorrichtung
IS2523B (is) Turn vindorkuvers
ATE435197T1 (de) Substituierte 4-aminocyclohexanole
DE60130137D1 (de) Kristallisationsverfahren
DE50214225D1 (de) Temperaturbegrenzer
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
FI20011778A0 (fi) Ryhmälähetyksen toteutus
DE60202381D1 (de) Paroxetin-n-formyl-derivate
DE60216967D1 (de) Substituierte cyclohexanderivate
NO20033761D0 (no) Silisium-krystallisasjon
ITGE20010022V0 (it) Orologio